NFE2L2 and diabetic kidney disease: In addition, diabetic kidney disease can be improved by β-hydroxybutyrate therapy by inhibiting glycogen synthase kinase-3 beta (GSK3β) and reactivating Nrf2 in glomerular podocytes [48].